Skip to main content
. Author manuscript; available in PMC: 2020 Oct 29.
Published in final edited form as: Curr Hematol Malig Rep. 2017 Aug;12(4):358–369. doi: 10.1007/s11899-017-0398-6

Figure 1: Improving Efficacy of CD30-redirected CAR-T Cells in HL.

Figure 1:

A. Lymphodepletion leads to decreased regulatory T cells and disruption of the inhibitory tumor environment. In addition, lymphodepletion increases levels of homeostatic cytokines such as IL-15 and Il-7 which stimulates CAR-T cell expansion.

B. PD-L1, which is expressed on HRS cells, interacts with PD-1, which is found on T cells including a subset of CAR-T cells, leading to inhibition of T cell receptor signaling. Antibodies to PD-1 will counter these inhibitory factors leading to improved expansion and persistence of CAR-T cells as well as increased activity of endogenous cytotoxic T cells.

C. HRS cells produce the chemokines TARC and MDC which attract Th2 cells and regulatory T cells that express CCR4. Further engineering CAR T cells to express the CCR4 molecule will improve their migration to tumor cells.